Literature DB >> 34559216

Discordance in patient and physician global assessment in relapsing polychondritis.

Emily Rose1, Marcela A Ferrada1, Kaitlin A Quinn1, Laurent Arnaud2, Wendy Goodspeed1, Jeff Kim3, Clint Allen4, Arlene Sirajuddin5, Marcus Chen5, Peter C Grayson1.   

Abstract

OBJECTIVES: Relapsing polychondritis (RP) is a rare, heterogeneous, systemic inflammatory disease that targets cartilage. Patient-reported outcome measures may differ from physician assessment. This study compared patient global assessment (PtGA) and physician global assessment (PhGA) scores in a prospective cohort of patients with RP.
METHODS: Adult patients with RP underwent a standardized comprehensive evaluation at ∼6 month intervals. At each visit, three physicians scored PhGA by consensus. The patient independently completed four patient-reported outcomes: PtGA, 36-item Short Form Health Survey (SF-36), Brief Illness Perception Questionnaire (BIPQ) and Multidimensional Fatigue Inventory (MFI). Patient-physician discordance was defined as a difference between PtGA and PhGA of ≥3 on a 0-10 scale.
RESULTS: A total of 76 patients were evaluated over 154 visits. The median PhGA was 3 [interquartile range (IQR) 2-3] and the median PtGA was 5 (IQR 4-7). PtGA and PhGA were concordant in 66 visits (42.9%) and patients scored disease severity ≥3 points higher than physicians scored disease activity (positive discordance) in 84 visits (54.5%). Compared with visits with concordance, visits with positive discordance were associated with significantly worse scores on the MFI, BIPQ, SF-36 physical component score and SF-36 mental component score.
CONCLUSION: Patients with RP typically self-report high PtGA that does not align with PhGA. Discordance is likely driven by the high physical and psychological burden of illness experienced by patients. Multifaceted treatment approaches that address the burden of disease in RP from the patient perspective are needed. Published by Oxford University Press on behalf of the British Society for Rheumatology 2021. This work is written by a US Government employee and is in the public domain in the US.

Entities:  

Keywords:  outcome measures; patient global assessment; relapsing polychondritis; vasculitis

Mesh:

Year:  2022        PMID: 34559216      PMCID: PMC9071565          DOI: 10.1093/rheumatology/keab587

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.046


  3 in total

Review 1.  Relapsing polychondritis: A 2016 update on clinical features, diagnostic tools, treatment and biological drug use.

Authors:  Alexis Mathian; Makoto Miyara; Fleur Cohen-Aubart; Julien Haroche; Miguel Hie; Micheline Pha; Philippe Grenier; Zahir Amoura
Journal:  Best Pract Res Clin Rheumatol       Date:  2016-10-01       Impact factor: 4.098

2.  Brief report: The value of a patient global assessment of disease activity in granulomatosis with polyangiitis (Wegener's).

Authors:  Gunnar Tomasson; John C Davis; Gary S Hoffman; W Joseph McCune; Ulrich Specks; Robert Spiera; E William St Clair; John H Stone; Peter A Merkel
Journal:  Arthritis Rheumatol       Date:  2014-02       Impact factor: 10.995

3.  "Like No One Is Listening to Me": A Qualitative Study of Patient-Provider Discordance Between Global Assessments of Disease Activity in Rheumatoid Arthritis.

Authors:  Zoran Kvrgic; Gladys B Asiedu; Cynthia S Crowson; Jennifer L Ridgeway; John M Davis
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-09-04       Impact factor: 4.794

  3 in total
  1 in total

1.  Extracorporeal high-frequency combined with contrast-enhanced ultrasound: a novel imaging method for detection and treatment evaluation of patients with cervical trachea-associated relapsing polychondritis.

Authors:  Jiaxing Tang; Weihua He; Yuxin Zhang; Qing Tang; Niantu He; Zechun Liang; Shiyue Li
Journal:  Ann Transl Med       Date:  2021-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.